₹527.2 crore for the quarter ended December 2020 on account of robust sales in all segments.The company had posted a net profit of ₹373.9 crore for the corresponding period of the previous fiscal, Cadila Healthcare said in a filing to BSE.Consolidated revenue of the company stood at ₹3,795.6 crore for the quarter under consideration.
It was ₹3,638.1 crore for the same period a year ago, it added.During the quarter, the company launched the oral anti-diabetic agent, Dapaglyn (Dapagliflozin) in India for patients suffering from Chronic Obstructive Pulmonary Disorder (COPD), the filing said.In a separate filing Cadila Healthcare said its board has approved reappointment of Apurva S Diwanji as an Independent Director of the company for the.